TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ).
Clarity Pharmaceuticals announced at its Annual General Meeting that it has raised $203 million in a recent capital raise, positioning the company strongly in the market. The funds will support ongoing clinical trials, including two Phase III trials for prostate cancer diagnostics, AMPLIFY and CLARIFY, and the development of their SAR-bisPSMA product, which has received three Fast Track Designations from the FDA. The company is also advancing other products in its pipeline, such as SARTATE and SAR-Bombesin, and is exploring new targets through its Discovery Program. Clarity’s strong patent position and focus on science and collaboration are expected to drive future growth and innovation in the oncology market.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd. is a clinical-stage radiopharmaceutical company focused on developing next-generation products to address the growing needs in oncology. The company is known for its innovative chelator technology and is actively involved in clinical trials to improve cancer diagnostics and treatment, particularly in prostate cancer. Clarity operates in the biotech sector and is listed on the Australian Securities Exchange (ASX).
Average Trading Volume: 2,633,460
Technical Sentiment Signal: Sell
Current Market Cap: A$1.33B
Learn more about CU6 stock on TipRanks’ Stock Analysis page.